Bayer Glyset (miglitol) antidiabetic is outlicensing candidate following Dec. 18 approval.
Executive Summary
BAYER GLYSET ORAL ANTIDIABETIC WILL BE OUTLICENSED OR CO-MARKETED, Bayer said following FDA approval of the Type II diabetes treatment Dec. 18. Bayer is discussing possible international marketing agreements, the firm said. Glyset (miglitol) has been approved in the European Union under the brand name Diastabol.